Bristol Myers SquibbBMYEarnings & Financial Report
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...
BMY Q1 FY2026 Key Financial Metrics
Revenue
$11.5B
Gross Profit
N/A
Operating Profit
N/A
Net Profit
$2.7B
Gross Margin
N/A
Operating Margin
N/A
Net Margin
23.3%
YoY Growth
11.0%
Bristol Myers Squibb Q1 FY2026 Financial Summary
Bristol Myers Squibb reported revenue of $11.5B (up 11.0% YoY) for Q1 FY2026, with a net profit of $2.7B (up 8.8% YoY) (23.3% margin).
Key Financial Metrics
| Total Revenue | $11.5B |
|---|---|
| Net Profit | $2.7B |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q1 FY2026 |
Bristol Myers Squibb Annual Revenue by Year
Bristol Myers Squibb annual revenue history includes year-by-year totals (for example, 2025 revenue was $48.2B).
Bristol Myers Squibb Quarterly Revenue & Net Profit History
Bristol Myers Squibb results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $11.5B | +11.0% | $2.7B | 23.3% |
| Q4 FY2025 | $12.5B | +1.3% | $1.1B | 8.7% |
| Q3 FY2025 | $12.2B | +2.8% | $2.2B | 18.0% |
| Q2 FY2025 | $12.3B | +0.6% | $1.3B | 10.7% |
| Q1 FY2025 | $11.2B | -5.6% | $2.5B | 21.9% |
| Q4 FY2024 | $12.3B | +7.5% | $72.0M | 0.6% |
| Q3 FY2024 | $11.9B | +8.4% | $1.2B | 10.2% |
| Q2 FY2024 | $12.2B | +8.7% | $1.7B | 13.8% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.20B | $11.89B | $12.34B | $11.20B | $12.27B | $12.22B | $12.50B | $11.49B |
| YoY Growth | 8.7% | 8.4% | 7.5% | -5.6% | 0.6% | 2.8% | 1.3% | 11.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $94.65B | $93.67B | $92.60B | $92.43B | $94.68B | $96.89B | $90.04B | N/A |
| Liabilities | $77.58B | $76.47B | $76.22B | $74.98B | $77.19B | $78.29B | $71.53B | N/A |
| Equity | $17.02B | $17.14B | $16.34B | $17.39B | $17.43B | $18.55B | $18.47B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $2.33B | $5.59B | $4.44B | $1.95B | $3.92B | $6.31B | $1.97B |